Drugs / fevipiprant
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03087942 | Jul 2017 → Aug 2018 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03048448 | May 2017 → Apr 2019 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 29 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT03989635 | Oct 2019 → Jun 2021 | asthma, eosinophil disorder | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT03810183 | May 2019 → Jan 2020 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03650400 | May → Dec 2019 | asthma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01785602 | Jun 2013 → Nov 2014 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01836471 | May 2013 → Feb 2016 | asthma | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01804400 | Oct 2012 → Oct 2013 | allergic rhinitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01545726 | Feb 2012 → Jun 2013 | asthma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01437735 | Aug 2011 → Nov 2013 | asthma | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01253603 | Nov 2010 → Sep 2011 | chronic asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 35 trials · 4 missed | ||||||
| Phase 3 | NCT03681093 | Mar 2019 → May 2020 | nasal cavity polyp | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT03629249 | Dec 2018 → Feb 2020 | asthma | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT03052517 | Mar 2017 → Feb 2020 | asthma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02555683 | Dec 2015 → Oct 2019 | asthma | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT02563067 | Dec 2015 → Jul 2019 | asthma | Novartis Pharmaceuticals | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03215758 Comparator | Nov 2017 → Jul 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03226392 Comparator | Oct 2017 → Jul 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-12-16 | Novartis Pharmaceuticals | Results Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma novartis.com ↗
The totality of these results do not support further development of fevipiprant in asthma. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-12-16 | Novartis Pharmaceuticals | Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma novartis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fevipiprant | “Dose-related efficacy and safety of fevipiprant (QAW039), an oral DP2 (CRTh2) receptor antagonist, was assessed in patients with allergic asthma uncontrolled by low-dose...” PMID 28838980 ↗ Aug 20178“Fevipiprant is an oral, non-steroidal, highly selective, reversible antagonist of the DP2 receptor that inhibits the binding of PGD2 and its metabolites.” PMID 34895218 ↗ Dec 2021 “QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care” NCT03810183 ↗ “fevipiprant (QAW039), an antagonist of prostaglandin D2 receptor 2” PMID 27503237 ↗ Aug 2016 “The oral CRTh2 antagonist QAW039 (fevipiprant)” PMID 27354118 ↗ Jun 2016 “fevipiprant (QAW039)” NCT03989635 ↗ |
| Known as | NVP-QAW039 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137332 ↗ |
| Known as | QAW039 | “The overall purpose of this study was to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when added to the Global Initiative...” NCT03052517 ↗15“QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care” NCT03810183 ↗ “Fevipiprant (QAW039) 150 mg once daily administered orally as tablet” NCT03681093 ↗ |
| Action | Inhibit | “QAW039, an oral chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) receptor antagonist” PMID 27354118 ↗ Jun 20161“G protein-coupled receptor 44 antagonist” CHEMBL3137332 ↗ |
| Modality | Small molecule | — CHEMBL3137332 ↗ |
| Route | Oral | “QAW039, an oral chemoattractant receptor-homologous molecule” PMID 27354118 ↗ Jun 2016 |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL3137332 ↗ |